Sodium-Glucose Cotransporter 2 Inhibitors
in the Treatment of Type 2 Diabetes
	 Volume 1 - Issue 3
		
		Nikolaos Papanas* and Theano Penlioglou
		
		
		
		      - 
                
				Author Information
Open or Close
                
				
				
		- Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
           
																
       	
       
*Corresponding author:
 Nikolaos Papanas, Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace,
University Hospital of Alexandroupolis, G Kondyli 22c, Alexandroupolis 68100, Greece
				
 
				 
                 
             
			
			 
			
			
			
				Received: June 20, 2018;   Published: June 27, 2018
             
      DOI:  10.32474/ADO.2018.01.000111
			 
			   		
			   
			   
			   Full Text
			   
			   
			   
			   PDF
			   
			   
				To view the Full Article    Peer-reviewed Article PDF
		
		Abstract
Over the past years, type 2 diabetes mellitus (T2DM) has become
a global pandemic, both in developed and developing countries
[1,2]. Its aetiology is multifactorial, including genetic factors,
increasing age, obesity and insulin resistance [3]. Among these
factors, obesity is of paramount importance, and its management
can be of benefit [4,5].
 
        
       
		
				    
        
Editorial|
Conflicts of Interest|
References|